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INTRODUCTION TO PROCEEDINGS
FROM A CONFERENCE ON
NEWBORN SCREENING FOR
NONTREATABLE DISORDERS
Maxwell J. Mehlmant
Newborn screening began in the 1960's after physician Robert
Guthrie developed a screening test for PKU, an autosomal recessive
metabolic disorder that can be treated effectively if detected soon after
birth. Guthrie also pioneered a method for collecting and transporting
on special filter paper the blood samples used for screening, known as
"Guthrie cards," and he insisted that the collection and analysis of the
samples be performed by state public health officials. Massachusetts
adopted newborn screening on a voluntary basis in 1962, but after
President Kennedy's Advisory Committee on Mental Retardation
recommended mandatory screening, states began to enact newborn
screening as a legal requirement. By 1973, newborn screening was
compulsory in 43 states. Now it is universal.
Newborn screening was justified originally on the basis that it
could detect disorders that could be successfully treated or mitigated
only if caught early in life. The development of faster and cheaper
technologies such as tandem mass spectrometry and microchip arrays,
however, enable programs to screen for far greater numbers of disorders, including many for which no readily effective treatments presently exist. Screening for these nontreatable disorders can be beneficial, in that it could spare families years of uncertainty once symptoms emerged; alert them to be on the watch for new discoveries that
could provide their children with treatment; provide children with
adjunctive if not curative interventions; and facilitate participation of
the children in research on their disorders. Yet some public health
advocates offer an additional rationale for screening for nontreatable
disorders: that it can serve as a valuable tool in family planning. One
recent article explains, for example: "Arguments for considering
broader benefits from the early diagnosis that only newborn screening
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can provide include ...knowledge on which to base reproductive
decision-making years before a disease would be diagnosed for the
affected child ... In short, nontreatable disorders would be included
in the screening panel in part in order to discourage parents from giving
birth to additional children with genetic disorders, and the authors make
it clear that one reason for this is to prevent these children from becoming a burden on society.
The question is whether this would be appropriate. In virtually all
states, newborn screening is compulsory. In 2005, for example, the
Nebraska Supreme Court rejected a constitutional challenge to newborn
screening based on religious grounds. 2 Government-mandated health
programs are justified historically on the basis as an exercise of the
state's police power aimed at preventing the spread of contagion. On
this basis, for example, the Supreme Court in 1905 sustained the constitutionality of compulsory vaccination. 3 But unless giving birth to a
child with genetic abnormalities is regarded as "spreading disease," it
cannot be justified on this basis. Moreover, mandatory screening by the
state for the purpose of preventing the birth of children with birth
defects may strike some as bearing too close a resemblance to the
discredited, state-sponsored eugenics programs of the early and mid20' h century. Indeed, the only constitutional precedent for it is the
infamous 1927 case of Buck v. Bell, 4 in which Justice Holmes upheld
the Virginia law that permitted forced sterilization of the supposedly
"feeble-minded." This law became the model for the Nazi eugenics
legislation enacted by the Reichstag following Hitler's election as
Chancellor of Germany.
On May 2, 2008, the Law-Medicine Center, with funding support
from the Inamori International Center for Ethics and Excellence and
the Center for Genetic Research Ethics and Law, both here at Case
Western Reserve University, held a workshop to consider the ethical,
legal, and social issues raised by the prospect of newborn screening
for nontreatable disorders. The workshop, the first of its kind, took
place in conjunction with a conference on ethical, legal, and social
issues in human genetics sponsored by the National Human Genome
Research Institute at the National institutes of Health. This issue of
Health Matrix presents the papers commissioned for this workshop.
The papers are by five of the leading experts in the field: Donald B.
Bailey, Distinguished Fellow, RTI (Research Triangle Institute) Inter' Duane Alexander (NIH) & Peter C. van Dyck (HRSA), A Vision of the
FutureofNewborn Screening, 117 PEDIATRICS S350, 352 (2006).
2 Douglas County v. Anaya, 694 N.W.2d 601 (Neb. 2005).
3 Jacobson v. Massachusetts, 197 U.S. 11 (1905).
4 Buck v. Bell, 274 U.S. 200 (1927).
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national; Jeffrey R. Botkin, MD, MPH; Professor of Pediatrics, University of Utah School of Medicine; Ellen W. Clayton, MD, JD; Rosalind E. Franklin Professor of Genetics and Health Policy at Vanderbilt
University; R. Rodney Howell, MD; Professor of Pediatrics, Miller
School of Medicine, University of Miami, Florida; and Marvin Natowicz, MD, PhD; Pediatric Geneticist; Clinical Pathologist; Vice
Chairman, Genomic Medicine Institute and Neurologist at the Cleveland Clinic.

